Neural signatures of stress resilience in emotion and cognitive domains: A meta-analysis of task-based fMRI studies.

Neurosci Biobehav RevJul 21, 2026 (epub)
Clinical ResearchPsychiatry

Kay Ke Fang, Viktor Enshuo Xu, Tatia Mei-Chun Lee et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined neural correlates of stress resilience in 1373 trauma-exposed individuals, revealing distinct patterns in emotion and cognitive domains. Resilience was linked to hypoactivity in the dorsomedial prefrontal cortex and limbic regions, while cognitive resilience showed hyperactivity in ventral prefrontal areas. The study highlights the complexity of resilience-related neural mechanisms.

Key findings

  • Resilience in the emotion domain was associated with hypoactivity in the dorsomedial prefrontal cortex and limbic regions.
  • Cognitive resilience showed hyperactivity in ventral prefrontal regions but hypoactivity in dorsal prefrontal and salience network regions.
  • Meta-regression analyses indicated moderating effects of age and sex on resilience-related neural activities.

Why it matters

Understanding the neural mechanisms underlying stress resilience can inform interventions aimed at improving mental health outcomes following trauma. Insights from this study may guide future research and therapeutic strategies.

Source

PubMed · PMID 42480683

Published in Neurosci Biobehav Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.